Clinical Trials · NCT02773381

A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
15
Start date
Jun 2016
Locations
1 site, United Kingdom
Primary endpoint
Area under the serum glucose concentration-time curve
View Semaglutide compound reference